Improved dihydroergotamine (DHE) pharmacology following orally-inhaled delivery

被引：0
|
作者：
Cook, R. O. [1 ]
Shrewsbury, S. B. [1 ]
机构：
[1] MAP Pharmaceut Inc, Res & Dev, Mountain View, CA USA
来源：
HEADACHE | 2008年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S62 / S63
页数：2
相关论文
共 50 条
  • [41] A Randomized, Double-Blind, Placebo-Controlled, Three-Period Crossover Study Comparing the Acute Effects of LEVADEX™ (MAP0004, Orally Inhaled DHE) and Intravenous DHE on Pulmonary Arterial Systolic Pressure
    Berenberg, E.
    Clemons, D.
    Kellerman, D.
    Kori, S.
    Noveck, R.
    HEADACHE, 2011, 51 : 23 - 23
  • [42] IMPORTANCE OF PHARMACOLOGY AND TOXICOLOGY TO PHARMACIST IN DELIVERY OF IMPROVED PATIENT CARE
    WEAVER, LC
    AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 1971, 35 (05) : 728 - &
  • [43] Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults
    Bodie, Susan
    Curran, Aidan K.
    Gonzalez-Nelson, Aaron C.
    Perry, Jason M.
    Manning, Debora C.
    Wasilewski, Margaret M.
    HEADACHE, 2024, 64 (06): : 643 - 651
  • [44] A drug interaction study assessing the effects of cyp3a4 inhibition on the pharmacokinetics of levadex™ (map0004 orally inhaled dhe) in healthy volunteers
    Forst, A.
    Kellerman, D.
    Kori, S.
    Febbraro, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    CEPHALALGIA, 2011, 31 (01) : 81 - 82
  • [45] Improved Quality Control Metrics for Cascade Impaction Measurements of Orally Inhaled Drug Products (OIPs)
    Terrence P. Tougas
    David Christopher
    Jolyon P. Mitchell
    Helen Strickland
    Bruce Wyka
    Mike Van Oort
    Svetlana Lyapustina
    AAPS PharmSciTech, 2009, 10 : 1276 - 1285
  • [46] Improved Quality Control Metrics for Cascade Impaction Measurements of Orally Inhaled Drug Products (OIPs)
    Tougas, Terrence P.
    Christopher, David
    Mitchell, Jolyon P.
    Strickland, Helen
    Wyka, Bruce
    Van Oort, Mike
    Lyapustina, Svetlana
    AAPS PHARMSCITECH, 2009, 10 (04): : 1276 - 1285
  • [47] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of LEVADEX™ (MAP0004, Orally Inhaled DHE) in Healthy Volunteers
    Forst, A.
    Kellerman, D.
    Kori, S.
    Febbraro, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    HEADACHE, 2011, 51 : 20 - 20
  • [48] A CLINICAL-TRIAL USING 5000 IU HEPARIN AND 0.5 MG DIHYDROERGOTAMINE (DHE) IN THE PROPHYLAXIS OF DEEP-VEIN THROMBOSIS FOLLOWING THORACIC-SURGERY
    RAJAH, SM
    DAVIES, GA
    SALTER, MCP
    DONALDSON, DR
    RAO, RS
    WATSON, DA
    THROMBOSIS AND HAEMOSTASIS, 1985, 54 (01) : 101 - 101
  • [49] Comparative clinical pharmacokinetics of parent drug and metabolites following inhaled dosing with dihydroergotamine mesylate via a novel system (Tempo™ inhaler)
    Shrewsbury, S. B.
    Cook, R.
    Taylor, G.
    Edwards, C.
    Ramadan, N.
    HEADACHE, 2007, 47 (05): : 754 - 754
  • [50] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of LEVADEX™ (MAP0004, orally inhaled dihydroergotamine) in Healthy Volunteers
    Kellerman, Don
    Forst, Amy
    Kori, Shashidhar
    Febbraro, Salvatori
    WuTann, Lan
    Thomas, Tracy
    Taylor, Glyn
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1365 - 1366
12345